PrintedbyFangThunderon5/30/201811:37:15PM.Forpersonaluseonly.Notapprovedfordistribution.Copyright''2018NationalComprehensiveCancerNetwork,Inc.,AllRightsReserved.
NCCNGuidelinesIndex
NCCNGuidelinesVersion2.2018
TableofContents
ThymomasandThymicCarcinomas
Discussion
168.WeideLG,UlbrightTM,LoehrerPJ,WilliamsSD.Thymic2012;69:309-315.Availableat:
carcinoma.Adistinctclinicalentityresponsivetochemotherapy.Cancerhttps://www.ncbi.nlm.nih.gov/pubmed/21710245.
1993;71:1219-1223.Availableat:
176.StrobelP,BargouR,WolffA,etal.Sunitinibinmetastaticthymic
http://www.ncbi.nlm.nih.gov/pubmed/8435796.
carcinomas:laboratoryfindingsandinitialclinicalexperience.BrJ
169.LucchiM,MussiA,AmbrogiM,etal.Thymiccarcinoma:areportCancer2010;103:196-200.Availableat:
of13cases.EurJSurgOncol2001;27:636-640.Availableat:http://www.ncbi.nlm.nih.gov/pubmed/20571495.
http://www.ncbi.nlm.nih.gov/pubmed/11669591.
177.BisagniG,RossiG,CavazzaA,etal.Longlastingresponsetothe
170.YohK,GotoK,IshiiG-i,etal.Weeklychemotherapywithcisplatin,multikinaseinhibitorbay43-9006(Sorafenib)inaheavilypretreated
vincristine,doxorubicin,andetoposideisaneffectivetreatmentformetastaticthymiccarcinoma.JThoracOncol2009;4:773-775.Available
advancedthymiccarcinoma.Cancer2003;98:926-931.Availableat:at:http://www.ncbi.nlm.nih.gov/pubmed/19461405.
http://www.ncbi.nlm.nih.gov/pubmed/12942558.
178.StrobelP,HartmannM,JakobA,etal.Thymiccarcinomawith
171.IgawaS,MurakamiH,TakahashiT,etal.EfficacyofoverexpressionofmutatedKITandtheresponsetoimatinib.NEnglJ
chemotherapywithcarboplatinandpaclitaxelforunresectablethymicMed2004;350:2625-2626.Availableat:
carcinoma.LungCancer2010;67:194-197.Availableat:http://www.ncbi.nlm.nih.gov/pubmed/15201427.
http://www.ncbi.nlm.nih.gov/pubmed/19409644.
179.GirardN.Targetedtherapiesforthymicmalignancies.ThoracSurg
172.KoizumiT,TakabayashiY,YamagishiS,etal.ChemotherapyforClin2011;21:115-123,viii.Availableat:
advancedthymiccarcinoma:clinicalresponsetocisplatin,doxorubicin,http://www.ncbi.nlm.nih.gov/pubmed/21070993.
vincristine,andcyclophosphamide(ADOCchemotherapy).AmJClin
180.OkumaY,ShimokawaT,TakagiY,etal.S-1isanactive
Oncol2002;25:266-268.Availableat:
anticanceragentforadvancedthymiccarcinoma.LungCancer
http://www.ncbi.nlm.nih.gov/pubmed/12040285.
2010;70:357-363.Availableat:
173.KandaS,KoizumiT,KomatsuY,etal.Second-linechemotherapyhttp://www.ncbi.nlm.nih.gov/pubmed/20951466.
ofplatinumcompoundplusCPT-11followingADOCchemotherapyin
181.KoizumiT,AgatsumaT,KomatsuY,KuboK.SuccessfulS-1
advancedthymiccarcinoma:analysisofsevencases.AnticancerRes
monotherapyforchemorefractorythymiccarcinoma.AnticancerRes
2007;27:3005-3008.Availableat:
2011;31:299-301.Availableat:
http://www.ncbi.nlm.nih.gov/pubmed/17695487.
http://www.ncbi.nlm.nih.gov/pubmed/21273614.
174.KomatsuY,KoizumiT,TanabeT,etal.Salvagechemotherapy
182.GiacconeG,KimC,ThompsonJ,etal.Pembrolizumabinpatients
withcarboplatinandpaclitaxelforcisplatin-resistantthymic
withthymiccarcinoma:asingle-arm,single-centre,phase2study.
carcinoma--threecases.AnticancerRes2006;26:4851-4855.Available
LancetOncol2018.Availableat:
at:http://www.ncbi.nlm.nih.gov/pubmed/17214351.
https://www.ncbi.nlm.nih.gov/pubmed/29395863.
175.PalmieriG,MarinoM,BuonerbaC,etal.Imatinibmesylatein
thymicepithelialmalignancies.CancerChemotherPharmacol
Version2.2018,02/16/18?NationalComprehensiveCancerNetwork,Inc.2018,Allrightsreserved.TheNCCNGuidelines?andthisillustrationmaynotbereproducedinanyformwithouttheexpresswrittenpermissionofNCCN?.MS-21 |
|
